Pharmaceutical Executive
Experts offer their opinion on how Takeda's Rozerem, the first non-controlled sleep aid, will be received by doctors and patients.
Pharmaceutical Executive-08-02-2005
Pharmaceutical Executive
Teva's recent purchase of Ivax has analysts wondering where the push for bigger and more global generic manufacturing companies will take the industry.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
